• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New antibiotic for cattle and swine is available

May 31, 2022

Tulathromycin injection is an option for bovine respiratory disease, and other conditions

Tulathromycin injection (Arovyn; Merck Animal Health) is now available to veterinarians. The prescription antibiotic is indicated for bovine respiratory disease (BRD) as well as foot rot and pinkeye, according to Merck.1

Merck Animal Health announced FDA approval of the drug in March 2022 for cattle and swine.2 Tulathromycin injection is available in 50-, 100-, 250- and 500-mL vials.1

In beef and nonlactating dairy cattle, tulathromycin injection is indicated for the treatment of BRD and control of respiratory disease in animals at high risk of developing BRD associated with Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis. It also is approved for treatment of infectious bovine keratoconjunctivitis—pinkeye— associated with Moraxella bovis, and treatment of foot rot associated with Fusobacterium necrophorum and Porphyromonas levii. In suckling calves, dairy calves, and veal calves, tulathromycin injection is indicated for treatment of BRD associated with M. haemolytica, P. multocida, H. somni and M. bovis.1,2

Advertisement

BRD is a condition known to be one of the costliest for beef cattle in North America and predisposes these animals to pneumonia. Risk factors for BRD include commingling, and purchase from sale barns. Calves at lighter weight and those that have been transported are at higher risk for BRD.3 

“[Tulathromycin injection] offers veterinarians and producers a new, cost-effective option for tulathromycin,” said David Sjeklocha, DVM, technical services manager, Merck Animal Health, in an organizational press release.1 “On-label to administer on arrival with high-risk cattle, [tulathromycin injection] can be used to treat BRD, foot rot and pinkeye—all of which are common and costly diseases.”

Tulathromycin injection should not be used in female dairy cattle aged 20 months or older. It has a preslaughter withdrawal time of 18 days in cattle and 5 days in swine, according to Merck Animal Health.1,2

References

  1. Merck Animal Health announces Arovyn is available. News release. May 24, 2022. Accessed May 31, 2022. https://www.merck-animal-health-usa.com/newsroom/merck-animal-health-announces-arovyn-is-available
  2. Merck Animal Health receives FDA approval of Arovyn. News release. March 3, 2022. Accessed May 31, 2022. https://www.merck-animal-health-usa.com/newsroom/merck-animal-health-receives-fda-approval-of-arovyn
  3. Taylor JD, Fulton RW, Lehenbauer TW, Step DL, Confer AW. The epidemiology of bovine respiratory disease: what is evidene for predisposing factors? Can Vet J. 2010;51(10):1095-1102. Accessed May 31, 2022. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2942046/#b1-cvj_10_1095

Related Content:

Respiratory MedicineOphthalmologyFDA
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
FDA and European Union expand Mutual Recognition Agreement to include animal drugs
Drug for acute onset of canine pancreatitis is launched on the US market
Drug for acute onset of canine pancreatitis is launched on the US market
FDA approves first monoclonal antibody for managing OA pain in dogs
FDA approves first monoclonal antibody for managing OA pain in dogs

Advertisement

Latest News

Research reveals efficacy of non-surgical contraceptive alternative for cats

Potential blood transfusion may offer lion chance of survival

Keeping pets safe from wildfire smoke

New report links pet ownership with human health care savings

View More Latest News
Advertisement